Overview

The Effects of Spironolactone on Calcineurin Inhibitor Induced Nephrotoxicity

Status:
Completed

Trial end date:
2021-04-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to assess whether the diuretic drug spironolactone can prevent chronic damage to transplanted kidneys caused by the medication that prevents rejection. Spironolactone prevents the effects of the hormone aldosterone. Aldosterone is suspected of being involved in the processes leading to chronic rejection of transplanted kidneys. Hence, by blocking the effects of aldosterone we hope to be able to prevent loss of kidney function in transplant patients.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Odense University Hospital

Collaborator:

Fredericia Hosptial

Treatments:

Calcineurin Inhibitors
Spironolactone

Criteria

Inclusion Criteria:

1. Age > 18 years

2. Proteinuria < 3 g/24 hours

3. Creatinine clearance ≥ 30 mL/min

4. S-Potassium < 5,5 mmol/L

5. Negative pregnancy test at the inclusion and anticonception

Exclusion Criteria:

1. Intolerance to spironolactone

2. Creatinine clearance < 30 ml/min

3. S-Potassium ≥ 5,5 mmol/L

4. Resin or digoxine treatment

5. Pregnancy or planned pregnancy

6. Relevant organic, systemic or mental illness

7. Anticipation of lack of compliance or understanding the study